What it is: 21 CFR Part 11 is the US Food and Drug Administration regulation governing the use of electronic records and electronic signatures in FDA-regulated clinical research. It sets requirements for system validation, audit trails, access controls, and signature integrity so that electronic data carries the same weight as a signed paper record.
How we comply: IAG’s imaging platform, DYNAMIKA, is validated to Part 11 requirements. Every read, measurement, and query is captured in a time-stamped, attributable audit trail that cannot be altered or overwritten. Access is role-based and individually authenticated, electronic signatures are bound to the signing user, and all validation, change-control, and periodic-review documentation is maintained and available for inspection.
Compliance status: IAG maintains a formal Declaration of Compliance with 21 CFR Part 11 for DYNAMIKA (Image Analysis Ltd, 2025), authorised by the Senior Product Manager and Chief Product Officer, supported by a full clause-by-clause compliance matrix. Note: Part 11 is a regulation, not an award — there is no FDA certificate to cite; this is a documented self-declaration backed by validation evidence.